START, Midwest

Clinical research site in Grand Rapids, Michigan · 750 FRONT AVE NW STE 311, GRAND RAPIDS, MI 49504-4400 · (616) 459-8971

As of July 2026, 73 paid clinical trials are recruiting at START, Midwest in Grand Rapids, Michigan. Active studies at this site cover conditions such as Colorectal Cancer, Advanced Solid Tumor and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at START, Midwest (73)

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for Breast Cancer

24 locations incl. Los Angeles

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

for Acute Leukemia

23 locations incl. Duarte

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 2+

Code: NCT04811560·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

for Cancer

16 locations incl. Denver

Sponsor: Tizona Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT04485013·Phase 1·Recruiting·Listed Jul 2020

Apply to this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

for Pancreatic Ductal Adenocarcinoma (PDAC)

16 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07644559·Phase 2·Recruiting·Listed Jun 12, 2026

Apply to this trial

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

11 locations incl. Birmingham

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07488676·Phase 1, Phase 2·Recruiting·Listed Mar 2026

Apply to this trial

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

for Endometrial Cancer

12 locations incl. Little Rock

Sponsor: Whitehawk Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07444814·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

for Multiple Myeloma (MM)

20 locations incl. Gilbert

Sponsor: C4 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07280013·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

for Multiple Myeloma

10 locations incl. Scottsdale

Sponsor: C4 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07284758·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

for Solid Tumors Harboring MET Amplification

17 locations incl. Beverly Hills

Sponsor: AbbVie

Sex: All·Age: 12+

Code: NCT07196644·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

for Advanced or Metastatic Solid Tumors

15 locations incl. Santa Monica

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT07205718·Phase 1, Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

for Bladder Cancer

12 locations incl. Duarte

Sponsor: EvolveImmune United, Inc

Sex: All·Age: 18+

Code: NCT07217171·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

for Small-cell Lung Cancer

13 locations incl. Denver

Sponsor: IDEAYA Biosciences

Sex: All·Age: 18+

Code: NCT07174583·Phase 1, Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

for Solid Tumor Malignancies

13 locations incl. La Jolla

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT07207707·Phase 1·Recruiting·Listed Oct 2025

Apply to this trial

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

for Colorectal Neoplasms

19 locations incl. Phoenix

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT06131840·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

for Advanced Solid Tumor

18 locations incl. Phoenix

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07070232·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

for Solid Malignancies

17 locations incl. Duarte

Sponsor: Immunome, Inc.

Sex: All·Age: 18+

Code: NCT06823167·Phase 1·Recruiting·Listed Feb 2025

Apply to this trial

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

for Non-Small Cell Lung Cancer

20 locations incl. Duarte

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05005403·Phase 1·Recruiting·Listed Aug 2021

Apply to this trial

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

for MTAP-deleted Solid Tumors

17 locations incl. Birmingham

Sponsor: Bayer

Sex: All·Age: 18+

Code: NCT06914128·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

for Solid Tumor

11 locations incl. Santa Monica

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT07094204·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

11 locations incl. Denver

Sponsor: Halda Therapeutics OpCo, Inc.

Sex: Male·Age: 18+

Code: NCT06800313·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

for Locally Advanced Breast Cancer

20 locations incl. Beverly Hills

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT06827236·Phase 1, Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

for GIST

11 locations incl. Los Angeles

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT05957367·Phase 1, Phase 2·Recruiting·Listed Jul 2023

Apply to this trial

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

for Relapsed Multiple Myeloma

12 locations incl. Gilbert

Sponsor: Opna Bio LLC

Sex: All·Age: 18+

Code: NCT06433947·Phase 1·Recruiting·Listed May 2024

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

18 locations incl. Orange

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for KRAS G12C Mutation

11 locations incl. Phoenix

Sponsor: Kumquat Biosciences Inc.

Sex: All·Age: 18+

Code: NCT06720987·Phase 1·Recruiting·Listed Dec 2024

Apply to this trial

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

for Solid Tumor Malignancies

13 locations incl. Denver

Sponsor: Tasca Therapeutics

Sex: All·Age: 18+

Code: NCT07030257·Phase 1, Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for Ovarian Cancer

14 locations incl. Denver

Sponsor: OnCusp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06234423·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

for Gastrointestinal Stromal Tumor (GIST)

10 locations incl. Scottsdate

Sponsor: Deciphera Pharmaceuticals, LLC

Sex: All·Age: 18+

Code: NCT06630234·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

for Advanced Solid Tumor

11 locations incl. Miami

Sponsor: Aulos Bioscience, Inc.

Sex: All·Age: 18+

Code: NCT05267626·Phase 1, Phase 2·Recruiting·Listed Mar 2022

Apply to this trial

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

for Advanced Solid Tumor

10 locations incl. Sarasota

Sponsor: Circle Pharma

Sex: All·Age: 12+

Code: NCT06577987·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

DBC-664 in Adult Patients With Solid Tumors Associated

for Malignant Germ Cell Tumor

3 locations incl. Grand Rapids

Sponsor: Duboce Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT07705035·Phase 1·Recruiting·Listed Jul 15, 2026

Apply to this trial

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

for Colorectal Cancer

5 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07659795·Phase 2·Recruiting·Listed Jun 22, 2026

Apply to this trial

First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )

for Triple Negative Breast Cancer (TNBC)

2 locations in Grand Rapids

Sponsor: Immunomic Therapeutics, Inc.

Sex: Female·Age: 18+

Code: NCT07652242·Phase 1·Recruiting·Listed Jun 17, 2026

Apply to this trial

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for Advanced NRAS-Mutant Melanoma

9 locations incl. Los Angeles

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07584226·Phase 1·Recruiting·Listed May 2026

Apply to this trial

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

for Hematologic Neoplasms

3 locations incl. Indianapolis

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07572006·Phase 1·Recruiting·Listed May 2026

Apply to this trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers

for Gastrointestinal Cancers

2 locations incl. Grand Rapids

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT07539311·Phase 2·Recruiting·Listed Apr 2026

Apply to this trial

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

for T Cell Malignancies

6 locations incl. New Haven

Sponsor: Electra Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT07465835·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

for Polycythemia Vera (PV)

5 locations incl. Denver

Sponsor: Prelude Therapeutics

Sex: All·Age: 18+

Code: NCT07469891·Phase 1·Recruiting·Listed Mar 2026

Apply to this trial

Showing the 40 most relevant of 73 recruiting trials at this site. Browse all with filters →

More research sites in Grand Rapids

Corewell Health Grand Rapids Hospitals - Butterworth Hospital (59 trials)
Trinity Health Grand Rapids Hospital (54 trials)
START Midwest (54 trials)
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital (52 trials)
Corewell Health (41 trials)
Helen DeVos Children's Hospital (16 trials)
BAMF Health (9 trials)
Helen DeVos Children's Hospital at Spectrum Health (8 trials)
START Midwest, LLC (8 trials)
Spectrum Health at Butterworth Campus (8 trials)

Explore more

Paid clinical trials in Grand Rapids, MI · Michigan clinical trials